Blog

Delta Gold Technologies PLC (AQSE:DGQ) (USOTC:DGQTF), a company focused on developing intellectual property in quantum computing, has agreed to bring forward C$269,000 in research funding to the University of Toronto, advancing part of its Year 2 sponsorship commitment ahead of the planned July 2026 timetable. The payment forms part of a broader C$1 million second-year funding obligation and reflects encouraging progress achieved by the university’s research team.

The early release of funds will support the integration of an additional component into the project’s cryogenic refrigeration system. This specialised system enables experiments to be conducted at ultra-low temperatures, creating stable environments required to test nano-scale material structures. Researchers are aiming to demonstrate foundational elements of a stable qubit using nano-scale gold combined with other materials. Achieving qubit stability remains one of the major technical challenges in quantum computing, underscoring the significance of the ongoing programme supported by Delta Gold.

Chief executive R. Michael Jones said: “We are pleased with the progress being made at the University of Toronto in our research using gold and other materials. Because of this, we have made the decision to make this advance which allows the research team to accelerate the experiments using the materials we have been designing and fabricating. I recently visited the lab at University of Toronto with our Principal Investigator Prof. Harry Ruda and it was amazing to see materials being worked on at the atomic level.”

Research partnership framework

Under the research sponsorship agreement, Delta Gold has committed to providing CAD $3 million in funding over three years to the University of Toronto. The arrangement grants the company exclusive rights to a 100% global licence for any intellectual property generated through the programme. The first-year payment of C$1 million has already been completed.

Leadership update

Delta Gold has also invited current non-executive director James Tosh to take on the role of executive director. In the expanded position, he is expected to work closely with CEO Michael Jones to advance operational execution and strategic development as the company moves toward commercialising its quantum computing technologies.

About Delta Gold Technologies

Delta Gold Technologies is developing intellectual property for applications within the quantum computing sector, centred on nano-scale gold and other advanced materials. The company collaborates with leading nanotechnology and quantum research groups worldwide to create patentable innovations intended for global licensing and commercial deployment within the rapidly evolving quantum computing industry.

SkinBioTherapeutics (LSE:SBTX), an AIM-listed UK life sciences company focused on skin health and microbiome-driven technologies, has appointed industry executive Rachel Parsonage as interim chief executive officer for an initial six-month period. Her appointment includes a planned position on the board, subject to standard regulatory approvals. The company develops cosmetic skincare products through its SkinBiotix platform and gut–skin health supplements under the AxisBiotix brand, while collaborating with Croda on the Zenakine active ingredient and expanding its capabilities through acquisitions that enhance manufacturing and distribution.

Executive chairman Martin Hunt said Parsonage’s experience in business turnaround and stakeholder engagement will support efforts to stabilise operations, oversee an ongoing forensic review into current business issues and reposition the group for renewed growth. Management expects the leadership transition to help restore operational focus and rebuild momentum as the company seeks to accelerate commercial progress.

SkinBioTherapeutics’ outlook remains shaped largely by financial challenges, including ongoing losses and negative cash flow, alongside a pronounced technical downtrend reflected in share price performance below major moving averages and negative MACD indicators. Strong revenue growth and a relatively conservative balance sheet provide some offset, though valuation remains constrained by a lack of profitability and the absence of dividend support.

More about SkinBioTherapeutics

SkinBioTherapeutics is a UK-based life sciences company specialising in skin health technologies built around its proprietary SkinBiotix platform, originally developed in collaboration with the University of Manchester. The company targets the skin healthcare market through cosmetic skincare products, gut–skin axis nutritional supplements and related dermatological applications.

Arrow Exploration (LSE:AXL) has reported higher production at the Mateguafa Attic field within Colombia’s Tapir block after successfully drilling and bringing online the M-10 vertical well and the M-9HZ horizontal appraisal well. Both wells are currently producing at restricted rates but have demonstrated the potential to deliver higher output as operations are further optimised.

The company is also advancing infrastructure improvements across the field, including converting the M-8 well into a water disposal facility to support ongoing development activity. Production from previously drilled Mateguafa wells remains strong, while additional drilling is planned at the M-11 location and at the Icaco exploration prospect. Arrow reported cash reserves of approximately US$7.2 million with no outstanding debt and confirmed ongoing constructive discussions regarding a potential extension of the Tapir block licence, highlighting the asset’s increasing importance within its Colombian growth strategy.

More about Arrow Exploration Corp

Arrow Exploration Corp. is a publicly listed oil and gas company focused on developing underexploited, high-growth light oil assets across Colombia’s Llanos, Middle Magdalena Valley and Putumayo basins. The company operates a predominantly operated portfolio with high working interests, Brent-linked pricing exposure and relatively low royalty structures, and holds entitlement to 50% of production from the Tapir block, subject to approval from Ecopetrol.

Power Metal Resources (LSE:POW) has completed a US$1.5 million strategic investment in Canadian exploration company Greyridge Exploration, securing an initial 4.6% equity stake. Greyridge holds 25 copper and gold exploration licences in Saudi Arabia, and the investment is accompanied by a memorandum of understanding that may lead to future joint ventures or earn-in arrangements across the licence portfolio, strengthening Power Metal’s exposure to exploration opportunities in the kingdom.

The new funding is expected to support exploration activity and drilling programmes at Greyridge’s Ad Dawadimi copper-gold project and the Al Amar gold-enriched volcanogenic massive sulphide (VMS) project, both situated close to established mining operations. Power Metal views the transaction as a step toward expanding its footprint in Saudi Arabia, a jurisdiction it considers increasingly attractive for mining investment due to supportive government policies and significant underexplored mineral potential. For Greyridge, the partnership provides capital backing and regional expertise aimed at accelerating development across its early-stage assets.

Power Metal Resources Plc’s outlook reflects improving revenue momentum and a relatively strong balance sheet, although operational challenges and ongoing negative cash flows continue to weigh on performance. The shares appear undervalued on certain measures, while technical indicators suggest a cautious stance amid broader bearish trends.

More about Power Metal Resources Plc

Power Metal Resources Plc is a London-listed mineral exploration and project incubation company with a diversified global portfolio of early-stage resource assets. Through its majority-owned subsidiary Power Arabia, the group has been expanding its presence within Saudi Arabia’s Arabian Shield, targeting precious and base metals as part of the country’s Vision 2030 strategy to diversify its economy and develop its mining sector.

Craneware (LSE:CRW) reported unaudited interim results for the six months ended 31 December 2025, highlighting steady revenue growth and improved profitability. Revenue increased 6% to $105.7 million, while adjusted EBITDA, profit before tax and earnings per share all recorded double-digit gains. Annual recurring revenue rose 4% to $184.2 million, with operating margins remaining above 30%. The company maintained a strong cash position, reduced bank debt and lifted its interim dividend by 11%, reflecting robust cash generation and balance sheet strength.

Operationally, Craneware continued to enhance its Trisus platform, including the development of advanced artificial intelligence capabilities in collaboration with Microsoft and the rollout of additional functionality planned for the second half of the year. The company also introduced what it described as the first fully integrated solution designed to address the evolving 340B rebate framework, despite the related pilot programme being postponed. Growth was supported by increased sales to new customers, net revenue retention of 103% and customer retention exceeding 90%. Management reinforced confidence in future performance with the announcement of a $25 million share buyback, signalling ambitions to further consolidate its position within the U.S. healthcare financial technology market.

Craneware’s outlook is underpinned by strong financial fundamentals, including healthy margins and a low-debt balance sheet. However, technical indicators remain weaker, with the share price trading below key moving averages and showing negative MACD momentum. Valuation metrics appear less supportive due to a relatively elevated price-to-earnings ratio, although dividend income provides some offset.

More about Craneware

Craneware plc is a UK-listed provider of healthcare financial performance software focused on hospitals and health systems in the United States. Through its Trisus cloud-based ecosystem, the company delivers revenue optimisation, analytics and 340B drug programme management tools designed to improve financial sustainability. A long-standing Microsoft partner, Craneware integrates proprietary data and AI technologies to help healthcare providers manage operational efficiency and regulatory complexity.

Tristel (LSE:TSTL) reported strong results for the six months ended 31 December 2025, with revenue increasing 14% to £25.65 million. Adjusted EBITDA rose 17% while adjusted profit before tax grew 11%, supported by robust gross margins of 81% and continued cash generation alongside a debt-free balance sheet. The company maintained its interim dividend during the period, with sales expanding across both domestic and international markets, led by strong demand for its medical device disinfectants and Cache surface disinfection range.

Performance in the United States was a key highlight, with revenue increasing more than sixfold, driven by accelerating adoption of the ULT ultrasound disinfection system, growing royalty income and updated US clinical guidance endorsing chlorine dioxide for high-level disinfection. During the period, Tristel also launched its OPH ophthalmic disinfectant in the US market, introduced the VISICLEAN cleaning product, brought wipe manufacturing in-house and appointed a new chief financial officer. Chief executive Matt Sassone confirmed plans to step down at the end of the year, although the company said the leadership transition is not expected to disrupt strategic execution.

Tristel’s outlook is supported primarily by strong financial delivery and a positive management outlook, which underpin its overall investment case. Technical indicators suggest some caution due to potentially overbought conditions, but continued strategic expansion and dividend stability reinforce a constructive longer-term growth profile. Valuation concerns are partly offset by the company’s growth trajectory and market positioning.

More about Tristel

Tristel plc is a global infection prevention specialist that develops and supplies disinfectant products based on proprietary chlorine dioxide chemistry. The company is a market leader in manual medical device decontamination and offers a sporicidal surface disinfection range designed as a more sustainable alternative to pre-wetted plastic wipes. Headquartered near Cambridge, Tristel operates in more than 40 countries through a network of 16 subsidiaries.

Great Western Mining (LSE:GWMO) is stepping up exploration activity at its Defender-Pine Crow tungsten project in Mineral County, Nevada, with the objective of delivering a maiden mineral resource estimate by the fourth quarter of 2026. The expanded programme follows encouraging recent assay results and is fully funded after a capital raise completed in January. Exploration will focus on evaluating a three-kilometre mineralised corridor connecting the Defender prospect with the existing M2 copper resource through a combination of geological mapping, geophysical surveys and drilling.

Field activities are scheduled to begin in March with detailed geological and geophysical work, ahead of drill pad construction planned for April and drilling expected to commence in June 2026. Management believes Defender could represent a large-scale tungsten opportunity within a relatively underexplored polymetallic district. The company intends to use forthcoming assay results and progress toward resource definition as catalysts for broader portfolio value, supported by investor engagement initiatives including an updated corporate presentation and live briefing.

The company’s outlook continues to be weighed down by financial fundamentals, including the absence of revenue, ongoing losses and steady cash outflows, although leverage remains low. Technical indicators appear more supportive, with the share price trading above key moving averages and showing moderately positive momentum. Valuation remains limited by negative earnings and the lack of dividend support.

More about Great Western Mining

Great Western Mining Corporation is a diversified exploration and development company focused on strategic mineral projects across multiple wholly owned claim groups in Mineral County, Nevada. Its portfolio includes copper, gold, silver and early-stage tungsten assets, highlighted by the Huntoon Copper Project and other projects aligned with growing U.S. critical minerals priorities.

Empire Metals (LSE:EEE) has taken part in the 2026 Western Australia Critical Minerals Delegation to North America, a government-supported initiative aligned with the U.S.–Australia Critical Minerals Framework designed to strengthen resilient and sustainable supply chains. As part of the programme, the company will showcase its Pitfield titanium project at PDAC’s Australia Day event in Toronto and participate in investor and industry meetings across New York and Washington, aiming to raise the project’s profile among North American stakeholders and reinforce its strategic relevance within the global critical minerals market.

The delegation reflects deepening cooperation between Australia and the United States on securing future supplies of key minerals, with Pitfield positioned as a potential contributor to long-term titanium supply security. Empire has also published an updated corporate presentation to support investor engagement efforts, highlighting the scale and grade of the project as demand for titanium and related critical minerals continues to grow worldwide.

The company’s outlook remains influenced by financial challenges typical of pre-revenue resource developers, including widening losses and increasing cash burn. These factors are partly balanced by strong technical momentum, with the share price trading above major moving averages and supported by positive MACD signals, alongside a conservatively structured balance sheet with minimal leverage. Valuation metrics remain constrained by negative earnings and the absence of dividend income.

More about Empire Metals

Empire Metals Limited is a resource exploration and development company focused on advancing the Pitfield Titanium Project in Western Australia. The project hosts one of the largest and highest-grade titanium mineral resources globally, with a 2.2 billion tonne Mineral Resource Estimate grading 5.1% TiO₂. The deposit benefits from near-surface mineralisation, consistent grade distribution and access to established infrastructure suitable for conventional processing into high-purity titanium products.